ImmunoGen, Inc. Announces Webcast of Presentation at the 7th Annual BioInvestor Forum

* Reuters is not responsible for the content in this press release.

Thu Oct 23, 2008 6:30am EDT 

WALTHAM, Mass.--(Business Wire)--
ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its
presentation at the 7th Annual BioInvestor Forum will be webcast live.
The presentation is scheduled to begin at 8:30 a.m. PDT on October 30,
2008, and will be given at the Palace Hotel, San Francisco, CA. The
presentation will provide an update on ImmunoGen.

   The webcast can be accessed through the "Investor Information"
section of the ImmunoGen website, http://www.immunogen.com. Following
the live webcast, a replay of the presentation will be available at
the same location until November 7, 2008.

   About ImmunoGen, Inc.

   ImmunoGen, Inc. develops targeted anticancer therapeutics using
its expertise in cancer biology, monoclonal antibodies and the
creation and attachment of potent cell-killing agents. The Company's
Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver
one of ImmunoGen's proprietary cell-killing agents specifically to
cancer targets. In addition to the Company's proprietary clinical
pipeline, ImmunoGen collaborators Genentech, sanofi-aventis, Biogen
Idec, and Biotest also are testing TAP compounds in the clinic, and a
naked antibody is in clinical trials through the Company's
collaboration with sanofi-aventis. Other ImmunoGen collaborative
partners include Bayer HealthCare and Amgen.

Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.